Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Paul Tennant is active.

Publication


Featured researches published by Paul Tennant.


Dysphagia | 2016

Pathophysiology of Radiation-Induced Dysphagia in Head and Neck Cancer

Suzanne N. King; N.E. Dunlap; Paul Tennant; Teresa Pitts

Oncologic treatments, such as curative radiotherapy and chemoradiation, for head and neck cancer can cause long-term swallowing impairments (dysphagia) that negatively impact quality of life. Radiation-induced dysphagia comprised a broad spectrum of structural, mechanical, and neurologic deficits. An understanding of the biomolecular effects of radiation on the time course of wound healing and underlying morphological tissue responses that precede radiation damage will improve options available for dysphagia treatment. The goal of this review is to discuss the pathophysiology of radiation-induced injury and elucidate areas that need further exploration.


Head and Neck-journal for The Sciences and Specialties of The Head and Neck | 2014

Persistent tracheostomy after primary chemoradiation for advanced laryngeal or hypopharyngeal cancer

Paul Tennant; Elizabeth Cash; Jeffrey M. Bumpous; K. Potts

Despite the demonstrated survival equivalence between chemoradiation and ablative surgery as primary treatment for advanced laryngeal and hypopharyngeal cancers, a subset of patients who undergo organ‐preservation therapy have persistent tracheostomy requirement after completion of treatment.


Head and Neck-journal for The Sciences and Specialties of The Head and Neck | 2016

Intraoperative goal-directed hemodynamic management in free tissue transfer for head and neck cancer

William R. Hand; William David Stoll; Matthew D. McEvoy; Julie R. McSwain; Clark Sealy; Judith M. Skoner; Joshua D. Hornig; Paul Tennant; Bethany J. Wolf; Terry A. Day

The purpose of this study was to determine the effect of algorithmic physiologic management on patients undergoing head and neck free tissue transfer and reconstruction.


Experimental and Molecular Pathology | 2015

Human papillomavirus E7 serology and association with p16 immunohistochemistry in squamous cell carcinoma of the head and neck

Sujita Khanal; Joongho Joh; Amy M. Kwon; Maryam Zahin; Cesar Augusto Perez; N.E. Dunlap; C.L. Silverman; Paul Tennant; K. Potts; Goetz H. Kloecker; Jeffrey M. Bumpous; Shin-je Ghim; Alfred B. Jenson; Rebecca Redman

BACKGROUND Human papillomavirus (HPV)-positive oropharyngeal cancer is associated with improved survival and treatment response as compared to HPV-negative cancers. P16 overexpression is widely accepted as a surrogate marker for HPV positivity. METHODS A total of 92 serum samples from 75 head and neck squamous cell carcinoma (HNSCC) patients were examined for HPV16 and 18 E7 antibodies by ELISA. Available tissue was tested for HPV-DNA by PCR, and p16 immunohistochemistry was obtained from a deidentified database. RESULTS Of 75 HNSCC patients, 25 were HPV E7 seropositive. Seropositivity was strongly associated with cancers of the oropharynx, and correlated with positive p16 immunohistochemistry (IHC) and HPV-DNA. Post-treatment serum was available in a limited subset of patients, revealing a decrease in antibody titers following response to treatment. CONCLUSIONS HPV E7 seropositivity correlated with positive tumor HPV-DNA and p16 expression, and was strongly associated with cancers of the oropharynx. E7 serology warrants further study as a potential biomarker in HPV-positive HNSCC.


Oral Oncology | 2017

High-dose versus weekly cisplatin definitive chemoradiotherapy for HPV-related oropharyngeal squamous cell carcinoma of the head and neck

Cesar Augusto Perez; Xiaoyong Wu; Mark J. Amsbaugh; Rahul Gosain; Wederson M. Claudino; Mehran Yusuf; T. Roberts; Dharamvir Jain; Alfred B. Jenson; Sujita Khanal; Craig I. Silverman; Paul Tennant; Jeffrey M. Bumpous; N.E. Dunlap; Shesh N. Rai; Rebecca Redman

OBJECTIVES To compare the outcomes and toxicity of high-dose cisplatin (HDC) versus weekly cisplatin (WC) definitive chemoradiotherapy (CRT) for patients with human papillomavirus (HPV) related oropharyngeal squamous cell carcinoma (SCCOPx). METHODS All patients with p16 positive SCCOPx treated with definitive CRT with cisplatin between 2010 and 2014 at a single institution were retrospectively reviewed. CTCAE v 4.03 toxicity criteria were used. The Kaplan-Meier method was used to estimate event-free survival (EFS) and the overall survival (OS). RESULTS Of the 55 patients included, 22 were patients treated with HDC at dose of 100mg/m2 on days 1 and 22; and the remaining 33 patients were treated with WC at 40mg/m2. Both cohorts received a median total dose of cisplatin of 200mg/m2. At median follow-up of 31months, there was one local failure and no distant failures in the HDC cohort. In the WC group, there were 6 total failures (2 local, 4 distant). Estimated 2-year EFS was better in HDC cohort as compared to WC (96% vs. 75%; p=0.04). There was no significant difference in 2-year OS (95% vs. 94%; p=0.40). Weight loss, gastric tube dependence at six months, acute renal injury and grade 3 or 4 hematological toxicity were all similar between both groups. CONCLUSIONS HPV-related SCCOPx treated with definitive CRT with either HDC or WC had similar toxicity profile. HDC had better EFS when compared with WC and this seems to be driven by increased distant failure rates, although the OS was similar.


Laryngoscope | 2017

Fungal contribution in chondroradionecrosis of the larynx

Mary Worthen; Mia Jusufbegovic; Jeffrey M. Bumpous; Andrew Vaughn; Elizabeth Cash; Xiu Yang; Craig Fichandler; Paul Tennant

To assess the prevalence of invasive fungal elements in the specimens of patients who underwent salvage total laryngectomy for chondroradionecrosis (CRN) in the absence of recurrent or persistent malignancy.


Current Surgery Reports | 2017

Evidence-Based Support for Nutrition Therapy in Head and Neck Cancer

Ryan Nesemeier; N.E. Dunlap; Stephen A. McClave; Paul Tennant

Purpose of ReviewPatients diagnosed with head and neck (H&N) cancer often present in a malnourished state for varied reasons; nutritional optimization is therefore critical to the success of treatment for these complex patients. This article aims to review the current nutrition literature pertaining to H&N cancer patients and to present evidence-based strategies for nutritional support specific to this population.Recent FindingsAggressive nutritional intervention is frequently required in the H&N cancer patient population. Rehabilitating nutrition during operative and nonoperative treatment improves compliance with treatment, quality of life, and clinical outcomes. When and whether to establishing alternative enteral access are points of controversy, although recent evidence suggests prophylactic enteral feeding tube placement should not be universally applied. Perioperative nutritional optimization including preoperative carbohydrate loading and provision of arginine-supplemented immunonutrition has been shown to benefit at-risk H&N cancer patients.SummaryWith multidisciplinary collaboration, H&N cancer patients can receive individualized nutritional support to withstand difficult cancer treatment regimens and return to acceptable states of nutritional health.


American Journal of Otolaryngology | 2017

ACS NSQIP risk calculator reliability in head and neck oncology: The effect of prior chemoradiation on NSQIP risk estimates following laryngectomy

Angela Cao; Sarah Khayat; Elizabeth Cash; Christopher Nickel; John Gettelfinger; Paul Tennant; Jeffrey M. Bumpous

PURPOSE To determine whether inclusion of chemoradiation history increases estimated risk for complications following total laryngectomy using the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) Surgical Risk Calculator. MATERIALS AND METHODS A retrospective review of 96 patients with laryngeal cancer, approximately half of who had received prior chemoradiation, who underwent laryngectomy between January 2010 and December 2014. NSQIP estimates were calculated and compared to actual event occurrence using receiver operating characteristic (ROC) curves, Brier scores, and risk estimates. RESULTS Patients who had received prior chemoradiation were at significantly greater risk for complication postoperatively (OR=2.63, 95% CI=1.145-6.043). NSQIP Calculator discriminability and accuracy were generally poor for this sample. While NSQIP estimates significantly predicted risk for any postoperative complication, pneumonia, and discharge to nursing care for primary laryngectomy patients, predictive capability was lost among salvage laryngectomy patients. NSQIP adjustments to both Somewhat Higher and Significantly Higher Risk categories did not improve predictive capability. Of the risk factors considered by NSQIP, preoperative functional status (p=0.041), age at time of surgery (p<0.008), and inclusion of neck dissection (p=0.035) emerged as significant predictors of actual postoperative complications, though again estimates lost significance among salvage laryngectomy patients. CONCLUSIONS The NSQIP Calculator may be poorly calibrated to estimate postoperative complication risk for patients previously exposed to chemoradiation undergoing salvage laryngectomy. Caution should be used when estimating postoperative risk among patients undergoing salvage procedures, especially those of older age, poorer functional status, and those requiring neck dissection.


Radiation oncology journal | 2016

Organ preservation with neoadjuvant chemoradiation in patients with orbit invasive sinonasal cancer otherwise requiring exenteration.

Mark J. Amsbaugh; Mehran Yusuf; C.L. Silverman; Jeffrey M. Bumpous; Cesar Augusto Perez; Keven Potts; Paul Tennant; Rebecca Redman; N.E. Dunlap

Purpose We sought to determine if organ preservation (OP) with neoadjuvant chemoradiation (CRT) was feasible in patients with sinonasal cancer determined to require exenteration. Materials and Methods Twenty patients were determined to require exenteration for definitive treatment from 2005 to 2014. Fourteen patients underwent OP and 6 patients received exenteration with adjuvant CRT. Exenteration free survival (EFS), locoregional control (LRC), progression-free survival (PFS), and overall survival (OS) were estimated. Results Five patients (36%) receiving OP had complete disease response at time of surgery. With a median follow-up of 18.8 months, EFS was 62% at 2 years for patients undergoing OP. At 2 years, there were no significant differences in LRC, PFS or OS (all all p > 0.050) between the groups. Less grade 3 or greater toxicity was seen in patients undergoing OP (p = 0.003). Visual function was preserved in all patients undergoing OP. Conclusion For patients with sinonasal cancer, OP may avoid exenteration, offering similar disease control and improved toxicity.


Journal of Clinical Oncology | 2016

High-dose versus weekly cisplatin definitive chemoradiotherapy for HPV-related oropharyngeal squamous cell carcinoma of the head and neck.

Cesar Augusto Perez; Xiaoyong Wu; Mark J. Amsbaugh; Wederson M. Claudino; Mehran Yusuf; T. Roberts; Jorge Arturo Rios-Perez; Dharamvir Jain; Alfred B. Jenson; Sujita Khanal; Craig I. Silverman; Paul Tennant; N.E. Dunlap; Shesh N. Rai; Rebecca Redman

Collaboration


Dive into the Paul Tennant's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

N.E. Dunlap

University of Louisville

View shared research outputs
Top Co-Authors

Avatar

Rebecca Redman

University of Louisville

View shared research outputs
Top Co-Authors

Avatar

C.L. Silverman

University of Louisville

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Elizabeth Cash

University of Louisville

View shared research outputs
Top Co-Authors

Avatar

K. Potts

University of Louisville

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mehran Yusuf

University of Louisville

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge